Details

Autor(en) / Beteiligte

• Karaaslan, Betul Gemici
• Turan, Isilay
• Aydemir, Sezin
• Meric, Zeynep Akyuncu
• Atay, Didem
• Akcay, Arzu
• Sari, Aysun Ayaz
• Hershfield, Michael
• Cipe, Funda
• Aksoy, Basak Adakli
• Ersoy, Gizem Zengin
• Bozkurt, Ceyhun
• Demirkol, Yasemin Kendir
• Ozturk, Gulyuz
• Aydogmus, Cigdem
• Kiykim, Ayca
• Cokugras, Haluk

Titel

Neurologic Status of Patients with Purine Nucleoside Phosphorylase Deficiency Before and After Hematopoetic Stem Cell Transplantation

Ist Teil von

• Journal of clinical immunology, 2023-11, Vol.43 (8), p.2062-2075

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Purine nucleoside phosphorylase (PNP) deficiency is a rare autosomal recessive combined immunodeficiency. The phenotype is profound T cell deficiency with variable B and NK cell functions and results in recurrent and persistent infections that typically begin in the first year of life. Neurologic findings occur in approximately two-thirds of patients. The mechanism of neurologic abnormalities is unclear. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for PNP deficiency. Methods We report here six patients from five unrelated families with PNP deficiency treated in two centers in Turkey. We evaluated the neurological status of patients and compared to post-transplantation period if available. Then, we performed PubMed, Google Scholar, and Researchgate searches using the terms “PNP” and “hematopoietic stem cell transplantation” to find all reported cases of PNP transplantation and compared to our cohort. Results Six patients were treated in two centers in Turkey. One patient died from post-transplant complications. The other four patients underwent successful HSCT with good immune reconstitution after transplantation (follow-up 21–48 months) and good neurological outcomes. The other patient with a new mutation is still waiting for a matching HLA donor. Discussion In PNP deficiency, clinical manifestations are variable, and this disease should be considered in the presence of many different clinical findings. Despite the comorbidities that occurred before transplantation, HSCT currently appears to be the only treatment option for this disease. HSCT not only cures immunologic disorders, but probably also improves or at least stabilizes the neurologic status of patients.